Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Ribocure Pharmaceuticals AB
AB
Active
Org 5593664377
Vetenskapens Gränd 11, 431 53
Mölndal
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2022 · 4 years old
50-99 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Ribocure Pharmaceuticals AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
108M
81M
54M
27M
0M
2022: 29M
29M
2022
2023: 61M (+110% vs 2022)
61M
+110%
2023
2024: 87M (+43% vs 2023)
87M
+43%
2024
EBITDA
SEK millions
8M
5M
2M
0M
-3M
2022: -1M
-1M
2022
2023: 2M (+300% vs 2022)
2M
+300%
2023
2024: 6M (+200% vs 2023)
6M
+200%
2024
Income statement
SEK thousands
Item
2024
2023
2022
Revenue
87 470
60 661
28 857
Staff expenses
—
—
—
EBITDA
5 701
1 638
−824
Depreciation & amort.
−2 886
−1 129
−28
EBIT
2 815
509
−852
Net financials
630
317
972
Profit before tax
3 445
827
120
Tax
−739
−216
−32
Net profit
2 706
611
88
Balance sheet
SEK thousands
Item
2024
2023
2022
Total assets
79 626
59 868
34 156
Equity
41 283
38 511
28 960
Long-term debt
0
0
0
Short-term debt
38 343
21 357
5 196
Total debt
38 343
21 357
5 196
Financial ratios
5-year trend
EBITDA margin
6,5 %
This company
15,8 %
Market median
This company
Market median
59% below market
2022
2024
Equity ratio
51,8 %
This company
38,2 %
Market median
This company
Market median
36% above market
2022
2024
Return on equity
6,6 %
This company
18,4 %
Market median
This company
Market median
64% below market
2022
2024
Net profit margin
3,1 %
This company
8,1 %
Market median
This company
Market median
62% below market
2022
2024
Asset turnover
1,10×
This company
1,12×
Market median
This company
Market median
2% below market
2022
2024
Debt / equity
0,93×
This company
0,62×
Market median
This company
Market median
50% above market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-02-01 – 2022-12-31
View
PDF
More on Ribocure Pharmaceuticals AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
